Inclusion Criteria:  Criteria for the multiple myeloma cohort  Patients with histologically or pathologically diagnosed multiple myeloma Patients who achieved CR, sCR, VGPR, and PR with induction therapy Criteria for the malignant lymphoma cohort Patients with histologically or pathologically diagnosed malignant lymphoma First or second CR or PR Multiple myeloma cohort, malignant lymphoma cohort common criteria Patients aged 20 to 75 years or younger at the time of informed consent  Exclusion Criteria:  Those who received allogeneic hematopoietic stem cell transplantation (Allo-SCT), autologous hematopoietic stem cell transplantation (ASCT), or CAR-T therapy Patients who have developed adverse events leading to discontinuation of hematopoietic stem-cell collection due to administration of granulocyte colony-stimulating factor (G-CSF) or apheresis Patients who have not been able to collect adequate amounts of hematopoietic stem cells with G-CSF or plerixafor administration Patients with hypersensitivity to G-CSF or plerixafor Patients with ECOG Performance status (PSs) of 2 or greater. Patients whose cardiac or pulmonary conditions were judged to be inappropriate for apheresis or ASCT. Pregnant or breastfeeding female patients